Methodology

All entries for: Investment

March 3, 2026

Aegle Therapeutics

Investment

Woburn MA
1-50 employees

Aegle Therapeutics received funding to advance AGLE-102 for the treatment of dystrophic epidermolysis bullosa (DEB), a rare disease.

City: Woburn
State: MA
Investment Amount(In Millions): $4.56

Source
February 17, 2026

NexEos Bio

Investment

NexEos Bio received a $3 million investment to advance NTX-1024, an ophthalmic solution for the treatment of the rare disease vernal keratoconjunctivitis (VKC)

Disease Area: Rare Diseases
Source
Source
January 21, 2026

Mendra

Investment

Mendra raised $82 million to apply artificial intelligence to the development of rare-disease drugs, accelerating discovery and commercialization.

Disease Area: Rare Diseases
Source
Source
January 12, 2026

Juvena Therapeutics

Investment

Juvena Therapeutics raised $79.5 million to advance protein-based therapeutics that restore cellular function and promote tissue repair for chronic and rare diseases.

Disease Area: Rare Diseases
Source
Source
January 9, 2026

Orca Bio

Investment

Orca Bio raised $250 million to advance the commercialization of Orca-T for the treatment of hematologic malignancies.

Disease Area: Rare Diseases
Source
Source
January 9, 2026

Aurora Therapeutics

Investment

Aurora Therapeutics raised $16 million to develop next-generation CRISPR-based gene-editing therapies that correct rare genetic mutations using customizable guide RNA technology.

Disease Area: Rare Diseases
Source
Source
January 8, 2026

Diagonal Therapeutics

Investment

Diagonal Therapeutics raised $125 million to advance DIAG723, designed to restore ALK1 signaling in hereditary hemorrhagic telangiectasia (HHT), addressing the root cause of abnormal blood vessel formation and chronic anemia.

Disease Area: Rare Diseases
Source
Source
January 7, 2026

STRM.BIO

Investment

STRM.BIO raised $8 million to advance its non-viral, cell-derived megakaryocyte vesicle delivery platform for in vivo genetic medicines, targeting rare hematologic diseases such as Fanconi anemia and CAR-T–based therapies.

Disease Area: Rare Diseases
Source
Source
December 29, 2025

Nacuity Pharmaceuticals

Investment

Nacuity Pharmaceuticals raised $12.89 million to advance drug candidates that target ocular oxidative stress in retinitis pigmentosa and other rare neurological disorders, enabling clinicians and patients to access improved therapeutic options and preserve vision.

Disease Area: Rare Diseases
Source
Source
December 23, 2025

Myrtelle

Investment

Myrtelle raised $30.53 to advance their gene therapy targeting oligodendrocytes to treat Canavan disease, a rare and fatal pediatric neurodegenerative disorder.

Disease Area: Rare Diseases
Source
Source
Scroll to Top